Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8491 to 8505 of 8944 results

  1. Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]

    In development Reference number: GID-TA11441 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]

    In development Reference number: GID-TA11585 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]

    In development Reference number: GID-TA11327 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]

    In development Reference number: GID-TA11400 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]

    In development Reference number: GID-TA11831 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]

    In development Reference number: GID-TA11368 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Botulinum toxin type A for preventing episodic migraine [ID6450]

    In development Reference number: GID-TA11505 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Electrochemotherapy for the treatment of malignant melanoma

    Discontinued Reference number: GID-IP1041

    Interventional procedures guidance
    Discontinued

  9. Extra corporeal membrane oxygenation for acute heart failure in children

    Discontinued Reference number: GID-IP1153

    Interventional procedures guidance
    Discontinued

  10. Intravaginal sling for stress urinary incontinence

    Discontinued Reference number: GID-IP267

    Interventional procedures guidance
    Discontinued

  11. Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]

    In development Reference number: GID-TA11663 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)

    Discontinued Reference number: GID-MT516

    Medical technologies guidance
    Discontinued

  13. Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]

    In development Reference number: GID-TA11745 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]

    In development Reference number: GID-TA11556 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Workplace health - older employees

    Discontinued Reference number: GID-PHG59

    NICE guideline
    Discontinued